GlassScriptPhysician profile
Jennifer Taylor
NPI 1417209941
$12,036.77
in general payments reported to CMS, 2019-2025
12 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $386 · 2023: $4,977 · 2024: $4,270 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $4,489 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $1,866 · Travel and Lodging: $1,172 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $4,489.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $1,865.82 |
| Travel and Lodging | $1,172.12 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,955.08 | 2022-2025 | |
| Uswm, LLC | $4,735.48 | 2022-2024 | Zimhi, Lucemyra |
| Indivior INC. | $351.04 | 2021-2025 | Sublocade |
| Braeburn INC. | $317.70 | 2024-2025 | Brixadi |
| Gilead Sciences, INC. | $232.55 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $130.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.61 | 2025 | Caplyta |
| Alkermes, INC. | $78.60 | 2022-2023 | Vivitrol |
| Emd Serono, INC. | $78.57 | 2021 | |
| Axsome Therapeutics, INC. | $31.44 | 2024 | Auvelity |
| Hologic Sales and Service, LLC | $21.99 | 2025 | Aptima |
| Neurocrine Biosciences, INC. | $19.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.